Mduma Emmanuel, Makwani Hellen, Msuya Said, Shao Eligi D, Ussiri Elijah, Kitinya James
Department of Clinical Oncology, Rabininsia Memorial Hospital, Dar es Salaam, Tanzania.
Department of Radiology, Rabininsia Memorial Hospital, Dar es Salaam, Tanzania.
Ann Med Surg (Lond). 2025 Mar 18;87(6):3842-3846. doi: 10.1097/MS9.0000000000003204. eCollection 2025 Jun.
Prostate cancer is the second most diagnosed malignancy (after lung cancer) in men worldwide. The most common site for metastasis of prostate cancer is bone (84%), followed by distant lymph nodes (10.6%), liver (10.2%), and lung being the least with 9.1%. Isolated lung metastasis is very rare and is present in less than 4.6% of metastatic prostate cancer. This is the first case of de novo isolated lung metastasis of prostate cancer in our setting.
We report a case of an 81-year-old male of African ethnicity who was diagnosed with isolated lung metastasis prostate adenocarcinoma. The total prostate specific antigen at the time of diagnosis was 182 ng/ml and grade group 3.
The prognosis of prostate cancer patients with pulmonary metastasis is reported to be limited. Prostate cancer patients with lung metastasis have median overall survival of approximately 19 months.
Although isolated pulmonary metastasis is rare in prostate cancer, it should not be excluded especially in patients with perineural invasion; however, further investigations are required to exclude metastasis to other sites.
前列腺癌是全球男性中第二大最常被诊断出的恶性肿瘤(仅次于肺癌)。前列腺癌最常见的转移部位是骨骼(84%),其次是远处淋巴结(10.6%)、肝脏(10.2%),肺部转移最少,为9.1%。孤立性肺转移非常罕见,在转移性前列腺癌中占比不到4.6%。这是我们所在地区首例前列腺癌新发孤立性肺转移病例。
我们报告一例81岁非洲裔男性,被诊断为前列腺腺癌孤立性肺转移。诊断时总前列腺特异性抗原为182 ng/ml,分级为3级。
据报道,前列腺癌肺转移患者的预后有限。前列腺癌肺转移患者的总中位生存期约为19个月。
尽管前列腺癌孤立性肺转移罕见,但不应排除,尤其是对于有神经周围侵犯的患者;然而,需要进一步检查以排除转移至其他部位。